Madrigal Pharmaceuticals (NASDAQ: MDGL ) has quickly become a major player in metabolic liver disease treatments with Rezdiffra (resmetirom), which is indicated for F2-F3 MASH. This drug was authorized under accelerated approval in the US and is already showing blockbuster potential. This is despite havingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohi ...